miR-30c and miR-21 fostered proliferation and reduced response to cisplatin by targeting BID and RASA141,42 while promoted invasive capabilities and EMT of NSCLC cells through RASA1, NF1, and RASSF8 downregulation. The gene discussed is NF1; the disease is non-small cell lung carcinoma.